|
Dr. Lina Yoo
| Affiliation: | Faculty |
| Title: | Associate Professor, Cell Biologist |
| Office: | 327 Talbot Hall |
| Lab: | 322 Talbot Hall |
| Email: |
|
| Phone: |
740-587-5803
|
| Fax: | 740-587-5634 |
Ph.D. in Immunology from Washington University in St. Louis, 2000
B.S. in Biology from Duke University, 1994
|
Academic Positions
Assistant Professor, Department of Biology at Denison University, 2005 - present
Teaching Assistant, Department of Biology at Washington University in St. Louis, St. Louis, MO, 1996
Research
Harvard Medical School, Boston, MA
Postdoctoral Research Fellow, Laboratory of Dr. Junying Yuan, 2000-2005
Washington University in St. Louis, St. Louis, MO
Predoctoral Student, Laboratory of Dr. Samuel Speck, 1994-2000
Duke University, Durham, NC
Undergraduate Independent Study, Laboratory of Dr. William Kane, 1993-1994
College of Wooster, Wooster, OH
COSEN Scholar Research, Laboratory of Dr. William Morgan, 1993
Research Focus
Cancer occurs when a combination of DNA mutations and abnormal gene expression in a cell leads to uncontrolled growth and invasion of surrounding tissues. It is critical to understand how mutations in individual genes, or more specifically, the series of events which occur as a result of those mutations, contribute to the development of tumors. My research focuses on a gene called Pten which is one of the most commonly mutated genes in human cancer. Previous work has shown that deletion or reduction in Pten function leads to increased cell proliferation, resistance to cell death, and heightened motility and invasiveness. I am interested in identifying the molecular changes which occur when Pten is mutated, and to elucidate the signaling pathways which are affected. In particular, I am studying the mechanism by which Pten deletion leads to increased cell size and the induction of the cyclin dependent kinase inhibitor p21. As a cell biologist, I use cell culture based methods in which Pten function can be reduced through the use of RNA interference, and assay for altered gene expression in candidate downstream pathways. I am also exploring the molecular basis for why certain tissues are much more susceptible than others to tumor development as a consequence of Pten mutation.
Publications
Elliott, J, EB Goodhew, LT Krug, N Rafael, L Yoo, and SH Speck. 2004. Variable methylation of the Epstein-Barr virus Wp EBNA gene promoter in B lymphoblastoid cell lines. J Virol. v. 78 p. 14062-5
Yoo, LI, J Woloszynek, S Templeton, and SH Speck. 2002. Deletion of Epstein-Barr virus regulatory sequences upstream of the EBNA gene promoter Wp1 is unfavorable for B-Cell immortalization. J Virology. v. 76 p. 11763-9
Yoo, LI, DC Chung, and J Yuan. 2002. LKB1--a master tumour suppressor of the small intestine and beyond. Nat Rev Cancer. v. 2 p. 529-35
Yoo, LI, and SH Speck. 2000. Regulation of EBNA gene expression. EBV Report. v. 7 no. p. 175-85
Yoo, L, and SH Speck. 2000. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines. J Virol. v. 74 p. 11115-20
Kung, C, JT Pingel, M Heikinheimo, T Klemola, K Varkila, LI Yoo, K Vuopala, M Poyhonen, M Uhari, M Rogers, SH Speck, T Chatila, and ML Thomas. 2000. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med. v. 6 p. 343-5
Kim, SW, TL Ortel, MA Quinn-Allen, L Yoo, L Worfolk, X Zhai, BR Lentz, and WH Kane. 1999. Partial glycosylation of asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. Biochemistry. v. 38 p. 11448-54
Yoo, LI, M Mooney, MT Puglielli, and SH Speck. 1997. B-cell lines immortalized with an Epstein-Barr virus mutant lacking the Cp EBNA2 enhancer are biased toward utilization of the oriP-proximal EBNA gene promoter Wp1. J Virol. v. 71 p. 9134-42
Weck, KE, ML Barkon, LI Yoo, SH Speck, and HW Virgin IV. 1996. Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus. J Virol. v. 70 p. 6775-80
Presentations
Yoo, LI. 2004. Characterization of mice conditionally deficient for Pten in urogenital epithelium. Society for Basic Urologic Research Meeting. Savannah, GA
Yoo, LI, D Liu, R Bronson, H Wu, and J Yuan. 2004. Pten-mediated tumor suppression in murine bladder epithelium. Cancer Genetics & Tumor Suppressor Genes Meeting. Cold Spring Harbor, NY
Yoo, LI, S LeVu, R Verman, H Wu, R Bronson, and J Yuan. 2003. Characterization of mice conditionally deficient for PTEN in urogenital epithelium. The Beatson International Cancer Conference. Glasgow, Scotland,
Yoo, LI, J Woloszynek, and SH Speck. 1999. Characterization of the EBV shared Cp/Wp enhancer. The 24th International Herpesvirus Workshop. Boston, MA
Yoo, LI, MA Mooney, and SH Speck. 1997. Regulation of EBV latency promoters by an EBNA2 responsive enhancer. The 22nd International Herpesvirus Workshop. San Diego, CA
Fellowships and Honors
- American Cancer Society postdoctoral fellowship grant "Dissection of the
- Molecular Functions of the LKB1 tumor suppressor gene." July 2001-June 2004.
- National Science Foundation Graduate Fellowship, Honorable Mention 1995.
- Carolinas-Ohio Science Education Network (COSEN) Scholar 1993
- Golden Key Honor Society 1993
- Phi Eta Sigma Honor Society 1991.
- Dean's List with Distinction 1991, 1992, 1994.
